Delivery Order SPE2DB24D1006-SPE2DB25FCDXZ

Award Date 11/22/24
Potential Completion Date 11/25/24
Potential Value $8.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of GARDASIL 9 syringes (0.5 mL). The firm-fixed-price delivery order, valued at $14,653.72, has a completion date of November 20, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of GARDASIL 9 syringes (0.5 mL). The contract, valued at $2,503.60, is a firm fixed-price delivery order with a completion date of June 14, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The...
This federal contract award, valued at $8,480.96, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of November 18, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued...
This federal contract award, valued at $33,135.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a pharmaceutical product, with a completion date of January 9, 2025. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $9,571.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with an ultimate completion date of October 6, 2023. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. This award is not designated as a set-aside contract. The contract is associated...
This federal contract award, valued at $4,867.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of December 16, 2024. The contract type is a Delivery Order with a Firm Fixed Price pricing structure. This award is a child contract under a larger Indefinite Delivery Contract (IDC) held...
This federal contract award, valued at $9,896.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of GARDASIL 9 SYRINGE 0.5ML. The contract is a delivery order awarded under a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December 2025, which enables DLA to efficiently procure a comprehensive range of medical commodities to support military treatment...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,239.30 delivery order contract is for the supply of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract has a firm fixed price pricing type and an ultimate completion date of July 16, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $18,158.00, is for the delivery of GARDASIL 9 vaccine syringes. It is a firm fixed-price delivery order contract with an ultimate completion date of January 23, 2025. The contract is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, to provide GARDASIL 9 syringes (0.5 ML) under a Firm Fixed Price Delivery Order contract. The award has a ceiling value of $4,874.64 and an ultimate completion date of February 25, 2025. The contract is not designated with a set-aside requirement, indicating open competition. AmerisourceBergen Drug Corp holds a $999,999,999 Indefinite Delivery...
  • SPE2DB24D1006
    Indefinite Delivery Contract
  • SPE2DB24D1006-SPE2DB25FCDXZ
    Delivery Order

This federal contract award, valued at $8,728.14, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp for the delivery of GARDASIL 9 syringes (0.5 mL). The contract has an ultimate completion date of November 25, 2024 and is a firm fixed-price delivery order. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract does not have a set-aside designation, indicating open competition.

Generated 5/20/25, 2:12 PM